Cécile Artaud has a Master’s degree in biomedical research from the University of Arkansas (USA, AR) completed with a university degree from the University of Sorbonne in Innovation and Entrepreneurship in Biomedical Engineering. She is now a clinical project manager with 15 years’ experience in academic vaccine development from basic research to clinical trials. She has been in charge of project conception, clinical operations, coordinating activities for GMP manufacturing, regulatory safety studies, and for preparing and conducting Phase I/II clinical trials inside and outside Europe. Clinical manager for the three Phase 1/2 clinical trials sponsored by Institut Pasteur in the last 5 years (cancer, infectious disease and gene therapy for a rare disease) she has developed a broad experience in diverse fields of expertise. She is also an expert clinical project manager in international translational research projects and has managed several sero-epidemiological projects and cohort studies in low and middle income countries (LMICs).
Vaccinology and Immunotherapy initiative
Vaccines have had a major positive impact on public health world-wide through disease prevention that can be measured in millions of lives saved. Despite the successes, we still face major challenges in vaccine and […]
The Healthy Human Global Project
Susceptibility to infections, disease progression and severity, and response to medical therapies and vaccines are highly variable from one individual to another. The complexity of individual immune responses is such that it has not […]
Projet de Recherche Clinique : Impact des mutations du gène APC (Adenomatous polyposis coli) dans les réponses immunes anti-tumorales
La polypose adénomateuse familiale est une maladie caractérisée par l’apparition dans l’intestin de nombreux polypes susceptibles d‘évoluer en cancer en l’absence de prise en charge. Il s’agit d’une maladie génétique rare, le plus souvent […]
CoSImmGEn-F : constitution d’une cohorte de sujets atteints de polypose adénomateuse familiale et porteurs d’une mutation du gène APC afin d’étudier le rôle de la génétique du système immunitaire et de l’environnement dans la maladie
Rationnel La polypose adénomateuse familiale se manifeste par l’apparition dans l’intestin de nombreuses excroissances dénommées polypes adénomateux et susceptibles d‘évoluer en cancers en l’absence de prise en charge. Il s’agit d’une maladie génétique, le […]
A synthetic carbohydrate-based conjugate vaccine ready for a clinical trial
A synthetic glycopeptide for anti-tumor immunotherapy: from design to first use in human
Within the framework of developing a carbohydrate-based vaccine against cancer, we designed and prepared the MAG-Tn3, a fully synthetic immunogen based on the tumor-associated Tn antigen. The MAG-Tn3 is a glycopeptide associating Tn clusters […]
Clinical development of cancer vaccines
CyaA-based therapeutic cancer vaccines Based on our discovery that a bacterial protein, the adenylate cyclase (CyaA), binds to dendritic cells (DCs), we have developed a highly efficient vector capable of targeting a wide range […]
2021Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome., Front Immunol 2021 ; 12(): 655478.
2018A multicenter, randomized controlled comparison of three renutrition strategies for the management of moderate acute malnutrition among children aged from 6 to 24 months (the MALINEA project), Trials 2018 Dec;19(1):666.
2017Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial, Lancet Neurol 2017 09;16(9):712-720.
2016Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate, Org. Biomol. Chem. 2016 Dec;15(1):114-123.
2016The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity, Cancer Immunol. Immunother. 2016 Mar;65(3):315-25.